secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001493152-24-042786
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma doses first three patients in Phase 2 trial of Ropidoxuridine for glioblastoma
--------------------------------------------------------------------------------

- First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma.
- Trial targets IDH wild-type, methylation-negative glioblastoma patients with no cure.
- Initial 40 patients randomized to 1,200 mg/day or 960 mg/day; then add 14 on optimal dose.
- Expected trial completion in 18-24 months.
- Orphan Drug Designation from FDA provides potential 7-year exclusivity if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224042786/0001493152-24-042786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315224042786/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer